Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
about
Targeting Cell Survival Proteins for Cancer Cell DeathOther targeted drugs in melanomaEmerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsCellular stress response and innate immune signaling: integrating pathways in host defense and inflammation.Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF-κB pathway proteins.Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsInduced protein degradation: an emerging drug discovery paradigm.Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells.MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balanceA first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.E6^E7, a novel splice isoform protein of human papillomavirus 16, stabilizes viral E6 and E7 oncoproteins via HSP90 and GRP78.The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic CancerA specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas.Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease.Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.Inflammatory stress and sarcomagenesis: a vicious interplay.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.GIST treatment options after tyrosine kinase inhibitors.Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.Targeting cancer cell mitochondria as a therapeutic approach: recent updates.BIIB021: A novel inhibitor to heat shock protein 90-addicted oncology.Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma.Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cellsHistone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.Current research and treatment for gastrointestinal stromal tumors.Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.New targets and therapies for gastrointestinal stromal tumors.Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives.Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape-Based Similarity Screening.Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma.Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches.
P2860
Q26765447-B5BAED9B-F281-45C1-875D-D6CE34E4225AQ26775594-B92C43B2-B5F4-448B-948D-DC487D478DACQ26799387-E9F8ABFC-4FC7-49F1-8EEA-0F33A74B8A2BQ27692108-11989BBA-BDD7-4A10-BA63-2F33EC40C6EFQ33410655-52234D78-CC30-420C-9317-4ED642583140Q33706374-2AFA63B6-22CE-41C9-B396-44C084FCD06BQ34164027-F7968339-70FA-49FF-9035-E9276EF70AA2Q34545841-54C1FDAD-2D22-4F37-ACA4-CEADB12A8C1FQ34629026-DAD06F60-5B28-49B0-8369-7605F27C37F0Q34957090-AE879CBC-44A6-4AFE-A48D-83D05FBBE23EQ35044980-0465D950-59B6-4D8F-86A8-4DDBD299D7D1Q35098333-4008FBBE-919E-4D76-8EC1-4CA8C2156077Q35111102-91026B15-2DB1-4ED9-A890-BA6678A576CFQ35336213-912AB5EC-EC30-46BE-847E-E0389C2BD858Q36125976-D3E3B9F0-8B87-46BC-81E8-FD2D93B2F9C4Q36540475-668A3292-4C78-40B0-AD85-6787F6A1115EQ37040615-A8E04497-2991-46BB-951E-1E91BF13E86CQ37198085-D873B18A-42D8-4F86-9A02-E78A8A92CCD4Q37204596-2CBC6AED-B138-4F90-AAC2-3502AB19B494Q37220191-70C6D3A4-155B-49EC-A239-01C5E52B41E7Q37245887-5A985D0C-AFED-491C-9ACD-AE6C992499ACQ37378867-B75E5D52-1041-4B4B-B526-B9116E6B0AF7Q38112821-D523ECC8-CA0B-43F1-8873-E945E4CD55C9Q38222205-6630AD31-6CA3-43FA-BEAC-4701C58515F3Q38502737-F186A4A0-6B0A-4685-8D2E-F696AA9B1F0EQ38527941-2C41D60B-7AB9-4974-B77A-3329A652B697Q38668524-48A2C346-98B6-4B5D-BF6E-52A6BF907B19Q39263075-ABBDF67E-63C1-4AD1-BF49-343D8EBF0737Q39288497-03009390-1DD6-47C0-89EE-D7831FA622C1Q40182987-C06775AC-2173-46E4-B012-952A84E44966Q41026661-9F0DF188-B5FB-4B47-8A7E-333C282C7724Q41127921-BEDCF7E3-8237-4EF8-A823-B690AABF54AEQ42337115-8C4332D9-D0F4-4E77-A737-9D04456C9CDEQ47097647-1357A48D-2763-4359-878E-9D5AA385E3DDQ47432725-CED8DD95-3747-434A-994D-A71C1F3D9712Q47694405-CE49A683-AB73-4192-89E8-A454E6046C0BQ51598140-677401CC-4BF2-44DD-88C0-EFEBCC3D6A86Q54355782-B4123ACC-CD13-4F5C-9149-77B2BCB23E3CQ54863183-1F5FD39E-4EE5-476A-AE9A-C394EE59CD91
P2860
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
@ast
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
@en
type
label
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
@ast
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
@en
prefLabel
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
@ast
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
@en
P2093
P2860
P356
P1433
P1476
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
@en
P2093
C R Antonescu
D R D'Adamo
G K Schwartz
M A Dickson
M L Keohan
T J Akhurst
P2860
P304
P356
10.1093/ANNONC/MDS275
P577
2012-08-16T00:00:00Z